Trial Profile
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Patritumab in Combination with Erlotinib in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Feb 2016
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Patritumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- 17 Feb 2016 New trial record